Vericiguat
Vericiguat, sold under the brand name Verquvo, is a medication used to reduce the risk of cardiovascular death and heart failure.
 | |
| Clinical data | |
|---|---|
| Trade names | Verquvo |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Guanylate cyclase activator |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.247.370  |
| Chemical and physical data | |
| Formula | C19H16F2N8O2 |
| Molar mass | 426.388 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It was approved for medical use in the United States in January 2021.[2]
References
- "Prescribing information" (PDF). www.accessdata.fda.gov. Retrieved 20 January 2021.
- "Verquvo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 19 January 2021.
Further reading
- Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. (May 2020). "Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction". N Engl J Med. 382 (20): 1883–1893. doi:10.1056/NEJMoa1915928. PMID 32222134.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.